Rodríguez de Santiago E, Burgos-Santamaria D, Pérez-Carazo L, Brullet E, Ciriano L, Pons FR, Ángel de Jorge Turrión M, Prados S, Pérez-Corte D, Becerro-Gonzalez I, Martinez-Moneo E, Barturen A, Fernández-Urién I, López-Serrano A, Ferre-Aracil C, Lopez-Ibañez M, Carbonell C, Nogales O, Martínez-Bauer E, Lantarón ÁT, Pagano G, Vázquez-Sequeiros E, Albillos A, TC-325 collaboration project. Endoscopy group of the Spanish Association of Gast, García AG, Volpato N, Rodriguez-Escaja C, García-Alonso FJ, Sevilla-Ribota S, Marcos Prieto HM, Chavarría-Herbozo CM, Murcia O, Aranda-Hernández J, Borobia R, Lledó JG, Santander C, Coto D, Oyón D, Polo IO, González-Haba Ruíz M, Torres CF, De Benito Sanz M, Peñas B, Parejo S, Juzgado D, and Ibañez A
Background and Aims: TC-325 (Hemospray, Cook Medical, Winston-Salem, NC) is an inorganic hemostatic powder recently approved by the U.S. Food and Drug Administration. This study aimed to examine the effectiveness, safety, and predictors of TC-325 failure in a large real-life cohort. Methods: This was a retrospective study conducted at 21 Spanish centers. All patients treated with TC-325 until September 2018 were included. The primary outcome was treatment failure, defined as failed intraprocedural hemostasis or recurrent bleeding within the first 30 postprocedural days. Secondary outcomes included safety and survival. Risk and predictors of failure were assessed via competing-risk models. Results: The cohort comprised 261 patients, of whom 219 (83.9%) presented with upper gastrointestinal bleeding (GIB). The most common causes were pepticulcer (28%), malignancy (18.4%), and therapeutic endoscopy-related GIB (17.6%). TC-325 was used as rescue therapy in 191 (73.2%) patients. The rate of intraprocedural hemostasis was 93.5% (95% confidence interval [CI], 90%-96%). Risks of TC-325 failure at postprocedural days 3, 7, and 30 were 21.1%, 24.6%, and 27.4%, respectively. On multivariate analysis, spurting bleeding (P = .004), use of vasoactive drugs (P = .02), and hypotension (P = .008) were independent predictors of failure. Overall 30-day survival was 81.9% (95% CI, 76%-86%) and intraprocedural hemostasis was associated with a better prognosis (adjusted hazard ratio, 0.29; P = .006). Two severe adverse events were noted. Conclusion: TC-325 was safe and effective for intraprocedural hemostasis in more than 90% of patients, regardless of the cause or site of bleeding and its use as rescue therapy. In this high-risk cohort treated with TC-325, the 30-day failure rate exceeded 25% and was highest with spurting bleeding or hemodynamic instability.